Author:
Goonewardene Sanchia S.,Ventii Karen,Bahl Amit,Persad Raj,Motiwala Hanif,Albala David
Publisher
Springer International Publishing
Reference12 articles.
1. Vemana G, Nepple KG, Vetter J, et al. Defining the potential of neoadjuvant chemotherapy use as a quality indicator for bladder cancer care. J Urol. 2014;192(1):43–9.
2. Mead GM. Bladder cancer. Curr Opin Oncol. 1990;2:514–9.
3. International Collaboration of Trialists. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29:2171–7.
4. Martinez-Pineiro JA, Leon JJ, Martin MG. Neoadjuvant cisplatinum in locally advanced urothelial bladder cancer: a prospective randomized study of the group CUETO. In: Splinter TAW, Scher HI, editors. Neoadjuvant chemotherapy in invasive bladder cancer. New York: Wiley-Liss; 1990. p. 95–103.
5. LAMB study, closed 2014, results pending.